Clinical Data Reinforce Safety and Efficacy of Boston Scientific's (BSX) Two Drug- Eluting Stent Platforms
Tweet Send to a Friend
Boston Scientific Corporation (NYSE: BSX) welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
